Abstract
Although serological studies have shown that antibodies against SARS-CoV-2 play an important role in protection against (re)infection, the dynamics of mucosal antibodies during primary infection and their potential impact on viral load and the resolution of disease symptoms remain unclear. During the first pandemic wave, we assessed the longitudinal nasal antibody response in index cases with mild COVID-19 and their household contacts. Nasal and serum antibody responses were analysed for up to nine months. Higher nasal receptor binding domain and spike protein-specific antibody levels at study inclusion were associated with lower viral load. Older age was correlated with more frequent COVID-19 related symptoms. Receptor binding domain and spike protein-specific mucosal antibodies were associated with the resolution of systemic, but not respiratory symptoms. Finally, receptor binding domain and spike protein-specific mucosal antibodies remained elevated up to nine months after symptom onset.
Original language | English |
---|---|
Article number | 5621 |
Pages (from-to) | 1-11 |
Journal | Nature Communications |
Volume | 12 |
Issue number | 1 |
DOIs | |
Publication status | Published - Dec 2021 |
Bibliographical note
Funding Information:We would like to thank all MuCo study participants for their willingness to participate and their support for the study. In addition, we thank M. Boonstra, M. Blok, D. van der Giessen, E. Lenssen, E. Reuvers, M. Roek and E. Wijnhoven for assisting with performing the first home visit, H. Lyoo from Utrecht University for experimental assistance, J. Heijnen, M. Dautzenberg and A. Voss for recruiting participants from the occupational health and safety officers at Rijnstate and CWZ hospitals, and the respective medical microbiology departments involved in PCR testing of hospital employees. This study was funded by the Laboratory of Medical Immunology, Radboud University Medical Center.
Publisher Copyright:
© 2021, The Author(s).